Reportlinker Adds Thyroid Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017
NEW YORK, April 14, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Thyroid Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Thyroid Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Summary
GlobalData, the industry analysis specialist, has released its new report, "Thyroid Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global Thyroid Cancer Therapeutics market. The report identifies the key trends shaping and driving the global Thyroid Cancer Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Thyroid Cancer Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Thyroid Cancer Therapeutics market. Its Scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Thyroid Cancer Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Thyroid Cancer Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Thyroid Cancer Therapeutics therapeutics market.
- Analysis of key recent licensing and partnership agreements in Thyroid Cancer Therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Thyroid Cancer Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Thyroid Cancer Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global Thyroid Cancer Therapeutics market landscape? – Identify, understand and capitalize.
1 Table of contents
1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 4
2 Introduction 5
2.1 Disease Overview 5
2.2 Epidemiology 9
2.3 Etiology 10
2.4 Symptoms 10
2.5 Diagnosis 11
2.6 Prognosis 12
2.7 Staging and Treatment of Thyroid Cancer 12
2.8 Treatment Options 17
2.9 GlobalData Pipeline Report Guidance 19
3 Thyroid Cancer Therapeutics: Market Characterization 20
3.1 Overview 20
3.2 Thyroid Cancer Therapeutics Market Size (2005-2010) - Global 20
3.3 Thyroid Cancer Therapeutics Market Forecast (2010-2017) - Global 21
3.4 Thyroid Cancer Therapeutics Market Size (2005-2010)- the US 22
3.5 Thyroid Cancer Therapeutics Market Forecast (2010-2017)- the US 23
3.6 Thyroid Cancer Therapeutics Market Size (2005-2010)- France 24
3.7 Thyroid Cancer Therapeutics Market Forecast (2010-2017)-France 25
3.8 Thyroid Cancer Therapeutics Market Size (2005-2010)- Germany 26
3.9 Thyroid Cancer Therapeutics Market Forecast (2010-2017)- Germany 27
3.10 Thyroid Cancer Therapeutics Market Size (2005-2010)- Italy 28
3.11 Thyroid Cancer Therapeutics Market Forecast (2010-2017)- Italy 29
3.12 Thyroid Cancer Therapeutics Market Size (2005-2010)- Spain 30
3.13 Thyroid Cancer Therapeutics Market Forecast (2010-2017)- Spain 31
3.14 Thyroid Cancer Therapeutics Market Size (2005-2010) – the UK 32
3.15 Thyroid Cancer Therapeutics Market Forecast (2010-2017) – the UK 33
3.16 Thyroid Cancer Therapeutics Market Size (2005-2010)- Japan 34
3.17 Thyroid Cancer Therapeutics Market Forecast (2010-2017)- Japan 35
3.18 Drivers and Barriers for Thyroid Cancer Therapeutics Market 36
3.19 Opportunity and Unmet needs 37
3.20 Key Takeaway 38
4 Thyroid Cancer Therapeutics: Competitive Assessment 39
4.1 Overview 39
4.2 Product Profile for the Major Off-Label Marketed Products in Thyroid Cancer 40
4.3 Key Takeaway 40
5 Thyroid Cancer Therapeutics: Pipeline Assessment 41
5.1 Overview 41
5.2 Strategic Pipeline Assessment 41
5.3 Pipeline Analysis by Phase of Development 41
5.4 Technology Trends Analytic Framework 45
5.5 Thyroid Cancer Therapeutics Market: Clinical Pipeline by Mechanism of Action 47
5.6 Promising Drugs Under Clinical Development 48
5.7 Key Takeaway 51
6 Thyroid Cancer Therapeutics: Clinical Trials Mapping 52
6.1 Clinical Trials by Country 52
6.2 Clinical Trials by Phase 53
6.3 Overall Sponsors 55
6.4 Top Sponsors Participating in Thyroid Cancer Therapeutics Clinical Trials 57
7 Thyroid Cancer Therapeutics: Strategic Assessment 58
8 Thyroid Cancer Therapeutics: Future Players 60
8.1 Introduction 60
8.2 Company Profiles for the Promising Drugs 61
8.3 Other Companies in the Thyroid Cancer Therapeutics Market 69
9 Thyroid Cancer Therapeutics: Licensing and Partnership Deals 70
10 Thyroid Cancer Therapeutics: Appendix 72
10.1 Market Definitions 72
10.2 Abbreviations 72
10.3 Research Methodology 73
10.4 Contact Us 77
10.5 Disclaimer 77
10.6 Bibliography 78
1.1 List of Tables
Table 1: Staging of Thyroid Cancer 12
Table 2: TNM Classification: Papillary Thyroid Cancer 13
Table 3: TNM Classification: Medullary Thyroid Cancer 15
Table 4: TNM Classification: Anaplastic Thyroid Cancer 17
Table 5: Thyroid Cancer Therapeutics Market, Global, Revenue ($m), 2005-2010 20
Table 6: Thyroid Cancer Therapeutics Market, Global, Forecast ($m), 2010-2017 21
Table 7: Thyroid Cancer Therapeutics Market, US, Revenue ($m), 2005-2010 22
Table 8: Thyroid Cancer Therapeutics Market, US, Forecast ($m), 2010-2017 23
Table 9: Thyroid Cancer Therapeutics Market, France, Revenue ($m), 2005-2010 24
Table 10: Thyroid Cancer Therapeutics Market, France, Forecast ($m), 2010-2017 25
Table 11: Thyroid Cancer Therapeutics Market, Germany, Revenue ($m), 2005-2010 26
Table 12: Thyroid Cancer Therapeutics Market, Germany, Forecast ($m), 2010-2017 27
Table 13: Thyroid Cancer Therapeutics Market, Italy, Revenue ($m), 2005-2010 28
Table 14: Thyroid Cancer Therapeutics Market, Italy, Forecast ($m), 2010-2017 29
Table 15: Thyroid Cancer Therapeutics Market, Spain, Revenue ($m), 2005-2010 30
Table 16: Thyroid Cancer Therapeutics Market, Spain, Forecast ($m), 2010-2017 31
Table 17: Thyroid Cancer Therapeutics Market, UK, Revenue ($m), 2005-2010 32
Table 18: Thyroid Cancer Therapeutics Market, UK, Forecast ($m), 2010-2017 33
Table 19: Thyroid Cancer Therapeutics Market, Japan, Revenue ($m), 2005-2010 34
Table 20: Thyroid Cancer Therapeutics Market, Japan, Forecast ($m), 2010-2017 35
Table 21: Thyroid Cancer Therapeutics – Pre-registration Phase, 2011 42
Table 22: Thyroid Cancer Therapeutics – Phase III Clinical Pipeline, 2011 42
Table 23: Thyroid Cancer Therapeutics – Phase II Clinical Pipeline, 2011 43
Table 24: Thyroid Cancer Therapeutics – Phase I Clinical Pipeline, 2011 44
Table 25: Thyroid Cancer Therapeutics – Preclinical Pipeline, 2011 44
Table 26: Thyroid Cancer Therapeutics – Discovery Pipeline, 2011 44
Table 27: Thyroid Cancer Therapeutics Market – Clinical Mapping by Country, 2011 52
Table 28: Thyroid Cancer Therapeutics Market – Clinical Mapping by Phase, 2011 53
Table 29: Thyroid Cancer Therapeutics Market – Clinical Mapping by Trial Status, 2011 54
Table 30: Thyroid Cancer Therapeutics Market – Clinical Mapping by Overall Sponsors, 2011 55
Table 31: Thyroid Cancer Therapeutics Market – Clinical Mapping by Prominent Sponsors, 2011 56
Table 32: Thyroid Cancer Therapeutics Market – Clinical Mapping by Top Sponsors, 2011 57
Table 33: AstraZeneca PLC. – Other Pipeline Products, 2011 62
Table 34: AstraZeneca PLC. – Thyroid Cancer Pipeline Product, 2011 62
Table 35: AstraZeneca PLC – Deals 62
Table 36: Bayer Schering Pharma – Other Pipeline Products, 2011 63
Table 37: Bayer Schering Pharma – Thyroid Cancer Pipeline Product, 2011 63
Table 38: Bayer Schering Pharma – Deals 64
Table 39: Exelixis, Inc. – Other Pipeline Products, 2011 66
Table 40: Exelixis, Inc. – Thyroid Cancer Pipeline Product, 2011 66
Table 41: Oxigene Inc. – Deals 66
Table 42: Oxigene, Inc – Other Pipeline Products, 2011 67
Table 43: Oxigene, Inc. – Thyroid Cancer Pipeline Product, 2011 67
Table 44: Oxigene Inc. – Deals 68
Table 45: Thyroid Cancer Therapeutics – Other Companies in the Thyroid Cancer Therapeutics Market, 2010 69
Table 46: Thyroid Cancer Therapeutics, Global, Deals, 2010 70
1.2 List of Figures
Figure 1: Classification of Papillary Thyroid Cancer 6
Figure 2: Classification of Follicular Thyroid Cancer 7
Figure 3: Incidence and Mortality for Thyroid Cancer in 2010 for Seven Major Markets 9
Figure 4: Thyroid Cancer Therapeutics Market, Global, Market Revenue ($m), 2005-2010 20
Figure 5: Thyroid Cancer Therapeutics Market, Global, Forecast ($m), 2010-2017 21
Figure 6: Cancer Therapeutics Market, the US, Revenue ($m), 2005-2010 22
Figure 7: Cancer Therapeutics Market, the US, Forecast ($m), 2010-2017 23
Figure 8: Cancer Therapeutics Market, France, Revenue ($m), 2005-2010 24
Figure 9: Thyroid Cancer Therapeutics Market, France, Forecast ($m), 2010-2017 25
Figure 10: Thyroid Cancer Therapeutics Market, Germany, Revenue ($m), 2005-2010 26
Figure 11: Thyroid Cancer Therapeutics Market, Germany, Forecast ($m), 2010-2017 27
Figure 12: Thyroid Cancer Therapeutics Market, Italy, Revenue ($m), 2005-2010 28
Figure 13: Thyroid Cancer Therapeutics Market, Italy, Forecast ($m), 2010-2017 29
Figure 14: Thyroid Cancer Therapeutics Market, Spain, Revenue ($m), 2005-2010 30
Figure 15: Thyroid Cancer Therapeutics Market, Spain, Forecast ($m), 2010-2017 31
Figure 16: Thyroid Cancer Therapeutics Market, the UK, Revenue ($m), 2005-2010 32
Figure 17: Thyroid Cancer Therapeutics Market, the UK, Forecast ($m), 2010-2017 33
Figure 18: Thyroid Cancer Therapeutics Market, Japan, Revenue ($m), 2005-2010 34
Figure 19: Thyroid Cancer Therapeutics Market, Japan, Forecast ($m), 2010-2017 35
Figure 20: Opportunity and Unmet Need in the Thyroid Cancer Therapeutics Market, 2010 37
Figure 21: Thyroid Cancer Therapeutics Pipeline by Phase of Clinical Development, 2011 41
Figure 22: Technology Trends Analytic Framework of the Thyroid Cancer Therapeutics Pipeline, 2011 45
Figure 23: Technology Trends Analytic Framework of the Thyroid Cancer Therapeutics Pipeline – Description, 2011 46
Figure 24: Thyroid Cancer Therapeutics Market – Clinical Pipeline by Mechanism of Action, 2011 47
Figure 25: Thyroid Cancer Market – Clinical Mapping by Country, 2011 52
Figure 26: Thyroid Cancer Therapeutics Market – Clinical Mapping by Phase, 2011 53
Figure 27: Thyroid Cancer Therapeutics – Clinical Mapping by Trial Status, 2011 54
Figure 28: Thyroid Cancer Therapeutics Market – Clinical Mapping by Overall Sponsors, 2011 55
Figure 29: Thyroid Cancer Therapeutics Market – Clinical Mapping by Prominent Sponsors, 2011 56
Figure 30: Thyroid Cancer Therapeutics Market – Clinical Mapping by Top Sponsors, 2011 57
Figure 31: Thyroid Cancer Therapeutics Market – Drivers and Barriers, 2010 58
Figure 32: Thyroid Cancer Therapeutics – Implications for Future Market Competition, 2010 59
Figure 33: Thyroid Cancer Therapeutics Market – Clinical Pipeline by Company, 2011 60
Figure 34: GlobalData Market Forecasting Model 76
To order this report:
: Thyroid Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article